In Brief: Wyeth-Ayerst Prempro
Executive Summary
Wyeth-Ayerst Prempro: Supplemental NDA for conjugated estrogens .625 mg/medroxyprogesterone acetate 5 mg tablet approved Jan. 9. Wyeth submitted the application on Jan. 8, 1997. Prempro is currently marketed for treatment of vasomotor menopausal symptoms, vaginal atrophy, and osteoporosis prevention in a .625/2.5 mg strength tablet...